The ability of Human IL-17A Neutralizing (D13C2) Rabbit mAb to inhibit IL-17A-induced IL-6 production was assessed. Human dermal fibroblasts were incubated with increasing concentrations of antibody in the presence of Human Interleukin-17A (hIL-17A) #8928 (15 ng/ml). After 48 hr, culture supernatants were harvested and assayed for IL-6 by ELISA and the OD450 was determined.Learn more about how we get our images
The production of IL-6 by human dermal fibroblasts cultured with increasing concentrations of Human IL-17A (hIL-17A) #8928 was assessed. Media from cells incubated with IL-17A for 48 hours was collected and assayed for IL-6 by ELISA and the OD450 was determined.Learn more about how we get our images
CST recommends incubation of the neutralizing antibody with the intended target for 1 hr at 37ºC before addition to the experiment at an optimal concentration determined by the user.
Lyophilized from a 0.2 µm filtered solution in 10 mM HEPES with trehalose.
Store lyophilized material at -20ºC. After reconstitution, recommended storage at 4ºC for 1 month or -20ºC for 6 months. Avoid repeated freeze/thawing.
Human IL-17A Neutralizing (D13C2) Rabbit mAb binds to human IL-17A (hIL-17A) and neutralizes its ability to induce IL-6 production in human dermal fibroblast cells. This antibody shows 50% cross-reactivity with human IL-17A/F. This antibody does not cross-react with mouse IL-17A, human IL-25 or mouse IL-25 .
Monoclonal antibody is produced by immunizing animals with a recombinant human IL-17A protein.
Neutralizing antibodies can be used to inhibit normal biological function through their binding to biological molecules. These reagents can be used to determine the effects that a particular molecule has in biological systems. Human IL-17A Neutralizing (D13C2) Rabbit mAb has been shown to neutralize the production of IL-6 from human dermal fibroblast cells in vitro with an ND50 in the range of 8-50 ng/ml.
Less than 0.1 EU/µg of antibody
IL-17A is a cystine-linked homodimeric pro-inflammatory cytokine produced by Th17 cells, a distinct CD4+ T cell lineage (1,2). IL-17A stimulates the production of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6. IL-17A also induces production of the neutrophil chemoattractants IL-8, CXCL1, and CXCL6 thereby bridging adaptive and innate immunity (1,2). IL-17A is intimately involved in mucosal immunity against bacterial infections (1,3) and has a putative role in some autoimmune disorders (1,4). IL-17A effects appear to be exerted primarily through binding to the IL-17RA (5). IL-17A binding induces production of cytokines, chemokines and other proteins through activation of the Erk1/2 MAP kinase, PI3K/Akt, p38, and NF-κB pathways (3,4,6).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Explore pathways related to this product.